PRMT3 and familial pancreatic carcinoma: In addition to GEM, PRMT3-overexpressing cancer cells also showed increased resistance to irinotecan, SN-38, and topotecan, indicating that upregulation of PRMT3 contributes to multidrug resistance in pancreatic cancer cells (Figure 1E).